Trastuzumab News and Research

RSS

Trastuzumab combined with trimodality treatment for HER2-overexpressing esophageal cancer found to be ineffective

The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 overexpressing esophageal adenocarcinoma.

22 Jan 2022

MR-guided focused ultrasound can safely deliver antibody therapy to Her2-positive brain metastases

In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, have demonstrated that magnetic resonance (MR)-guided focused ultrasound can be used to safely deliver antibody therapy to breast cancer that has metastasized to the brain.

13 Oct 2021

New antibody conjugate delivers drugs to bone tumors and inhibits metastasis

Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.

23 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

New radiopharmaceutical shows therapeutic efficacy in preclinical model of ovarian cancer

Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.

11 Jun 2021

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells. Unlike chemotherapy or radiotherapy, this approach does no harm to normal healthy cells.

18 May 2021

The Christie NHS Foundation Trust first to offer treatment in cancer patients’ homes

One of Europe’s largest cancer centres, The Christie NHS Foundation Trust, has become the first in the country to provide a treatment called Phesgo for breast cancer patients in their own homes. Phesgo is a combination of Herceptin

30 Apr 2021

Cholesterol-lowering drugs may protect women's hearts from damage caused during chemotherapy

Statins, common cholesterol-lowering medications, may protect women's hearts from damage caused during chemotherapy for early-stage breast cancer, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.

6 Jan 2021

Statins may protect the heart from damaging side-effects of early breast cancer treatment

New research from UHN's Peter Munk Cardiac Centre (PMCC) shows statins, commonly prescribed to lower cholesterol and reduce the risk of heart disease and stroke, may also protect the heart from damaging side-effects of early breast cancer treatment.

6 Jan 2021

Researchers identify a potential target for small cell lung cancer

The cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.

1 Oct 2020

Patients with invasive lobular carcinoma could benefit from additional adjuvant therapy

New results presented at the 12th European Breast Cancer Conference show that a test, which looks at the activity of 70 genes in breast cancer tissue, is possible to use in the clinic to identify patients with invasive lobular carcinoma (ILC) that is at high risk of recurring and progressing.

1 Oct 2020

New material identifies cancer cells and mounts a surprising attack

Many people across the globe are working hard to get the better of cancer; however cancer is always working too. Cancer cells can become resistant to the methods that have been adopted to kill them, so identifying drugs that act in different ways is part of the push to outsmart this ubiquitous disease

25 Sep 2020

Sub-Saharan Africa needs greater access to live-saving antibodies

Sub-Saharan Africa must increase access to live-saving, laboratory-produced antibodies, writes Yolanda Moyo.

16 Sep 2020

Reducing the incidence of drug-induced interstitial lung disease in breast cancer patients

Announcing a new article publication for BIO Integration journal. In this case report the authors Zijun Zhao, Zhanghai He, Hongyan Huang, Jiewen Chen, Shishi He, Ailifeire Yilihamu and Yan Nie from Sun Yat-sen University, Guangzhou, China consider drug-induced interstitial lung disease in breast cancer patients.

27 Jul 2020

Combination therapy improves survival rates for women with aggressive endometrial cancer

Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

29 Jun 2020

Rice lab's fluorescent tag project reveals new method to kill tumors

A Rice University lab's project to make better fluorescent tags has turned into a method to kill tumors. Switching one atom in the tag does the trick.

11 Jun 2020

Trastuzumab emtansine as a preferred second-line choice after horizontal dual blockade

Volume 11, Issue 22 of Oncotarget reported that despite relevant medical advancements, metastatic breast cancer remains an incurable disease.

3 Jun 2020

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.

29 May 2020

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.